(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 26.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ocular Therapeutix's revenue in 2025 is $59,646,000.On average, 5 Wall Street analysts forecast OCUL's revenue for 2025 to be $9,009,037,270, with the lowest OCUL revenue forecast at $8,345,713,169, and the highest OCUL revenue forecast at $10,800,522,101. On average, 5 Wall Street analysts forecast OCUL's revenue for 2026 to be $11,073,243,249, with the lowest OCUL revenue forecast at $9,360,452,487, and the highest OCUL revenue forecast at $14,910,455,290.
In 2027, OCUL is forecast to generate $21,036,485,937 in revenue, with the lowest revenue forecast at $10,418,202,734 and the highest revenue forecast at $27,383,624,618.